← Anti-obesity drugs × body weight & composition

SynthesisJAMA2016

Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis.

Rohan Khera et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedrandomised · 18 people · 2016

Randomised comparison

Probably raised body weight & composition

9.2×6.6× to 13×

Bigger than almost all on the map

As reported

OR 9.22, 95% CI 6.63–12.8

Randomised comparison

Probably raised body weight & composition

5.5×4.2× to 7.8×

Bigger than almost all on the map

As reported

OR 5.54, 95% CI 4.16–7.78

Randomised comparison

Probably raised body weight & composition

4×3× to 5.1×

Bigger than 9 in 10 on the map

As reported

OR 3.96, 95% CI 3.03–5.11

Randomised comparison

Probably raised body weight & composition

3.1×2.4× to 4×

Bigger than 9 in 10 on the map

As reported

OR 3.10, 95% CI 2.38–4.05

+4 more in the walkthrough ↓

Eight numbers in the abstract

the abstract, start to end

… phentermine-topiramate (odds ratio [OR], 9.22; 95% credible interval [CrI], 6.63-12.85; SUCRA, 0.95), 63% of participants taking liraglutide (OR, 5.54; 95% CrI, 4.16-7.78; SUCRA, 0.83), 55% taking naltrexone-bupropion (OR, 3.96; 95% CrI, 3.03-5.11; SUCRA, 0.60), 49% taking lorcaserin (OR, 3.10; 95% CrI, 2.38-4.05; SUCRA, 0.39), and 44% taking orlistat (OR, 2.70; 95% CrI, 2.34-3.09; SUCRA, …

… at 1 year-phentermine-topiramate, 8.8 kg (95% CrI, -10.20 to -7.42 …

Compared with placebo, liraglutide (OR, 2.95; 95% CrI, 2.11-4.23) and naltrexone-bupropion (OR, 2.64; 95% CrI, 2.10-3.35) were …

← favours treatmentfavours comparator →
could be chance
Body weight & composition
OR 9.226.63–12.8
Body weight & composition
OR 5.544.16–7.78
Body weight & composition
OR 3.963.03–5.11
Body weight & composition
OR 3.102.38–4.05
Body weight & composition
OR 2.702.34–3.09
Body weight & composition
−8.80−10.2 to −7.42
Adverse events & safety
OR 2.952.11–4.23
Adverse events & safety
OR 2.642.10–3.35
GLP-1 receptor agonistsAnti-obesity drugsBody weight & compositionAdverse events & safety

Anti-obesity drugs × body weight & compositionhelps?replicated

unlikelylikely
0.99not counted

GLP-1 receptor agonists × body weight & compositionhelps?replicated

unlikelylikely
0.91not counted

GLP-1 receptor agonists × adverse events & safetyharms?mixed

unlikelylikely
0.00not counted
← favours treatmentfavours comparator →
more certainless certain
1 / 5

370 papers cite itlatest 60 shown

2016
…
2022
2023
2024
2025
2026
this paperpooled ittrialcites it

2 trials

NCT04501198150 enrolled2020NCT0483518168 enrolled2021
Full record →Abstract, authors, funding and every citing paper · PMID 27299618